PMID: 6973599Aug 1, 1981Paper

Loss of tumor-specific and idiotype-specific immunity with age

The Journal of Experimental Medicine
P M FloodH Schreiber

Abstract

The ultraviolet light-induced fibrosarcoma 1591 undergoes "first-set rejection" when transplanted into normal syngeneic mice. We found, however, that the primary resistance of normal mice decreases with age, beginning at 9--12 mo, equivalent to middle age for mice. Mice lose with age the capacity to mount both idiotypic and anti-idiotypic responses responsible for controlling the growth of tumor. This loss was correlated with quantitative as well as qualitative changes in the response, such as changes in specificity and clonotype. Normal young mice regularly expressed a dominant common anti-1591 "idiotype" as defined by an anti-idiotypic probe. The capability of normal mice to respond with lymphocytes of this dominant common idiotype began to decline at about 8 mo of age. At this time, animals still generated tumor-specific lymphocytes, but these lymphocytes appear to be idiotypically different lymphocyte clones. With further increase in age, animals responded with tumor-reactive lymphocytes that showed a marked cross-reactivity to other tumor target cell lines. Both in vivo and in vitro, the capability of normal mice to mount an immune response that was specific for the 1591 tumor cells decreased between 9 and 14 mo, which was...Continue Reading

References

Apr 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·M S Fisher, M L Kripke
Jan 1, 1979·Journal of Immunological Methods·S N HurtW Clark
Sep 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·H Cosenza, H Köhler
Apr 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P M FloodH Schreiber

❮ Previous
Next ❯

Citations

Jul 1, 1983·Mechanisms of Ageing and Development·M A Hollingsworth, D L Evans
Sep 1, 1992·Experimental Gerontology·W B Ershler
Aug 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·M McMillanD M Rovner
Oct 1, 1982·The Journal of Experimental Medicine·J L UrbanH Schreiber
Oct 23, 1997·Journal of the National Cancer Institute·W B Ershler, D L Longo
Feb 26, 1998·Immunological Reviews·N R Klinman, G H Kline
Jan 24, 2013·Proceedings of the National Academy of Sciences of the United States of America·Joanna J ListopadThomas Blankenstein
Dec 24, 2008·Vaccine·David N PosnettAlan N Houghton
May 1, 1988·Cancer·W B ErshlerK E Kramer
Jul 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lyse A Norian, Paul M Allen
Oct 15, 1983·International Journal of Cancer. Journal International Du Cancer·H BinzH Wigzell
Apr 15, 1982·International Journal of Cancer. Journal International Du Cancer·H BinzH Wigzell
Feb 1, 1984·European Journal of Immunology·J L UrbanH Schreiber
Jun 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik LadomerskyDerek A Wainwright
Mar 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karin SchreiberHans Schreiber
Nov 3, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ibtissam AcemUNKNOWN PERSARC study group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

© 2021 Meta ULC. All rights reserved